Innovative wearable transitions to clinical applications, enhancing health monitoring for providers and researchers.
Movano Health’s EvieMED Ring has achieved FDA 510(k) clearance for its pulse oximeter, enabling the company to expand beyond consumer markets into clinical applications. Designed for continuous wear and enhanced compliance, the device supports clinical trials, remote patient monitoring, and high-risk patient management.
A Breakthrough in Health Monitoring
The EvieMED Ring combines medical-grade accuracy with the comfort of a wearable, offering a range of benefits:
- Pulse oximetry: Accurately measures SpO2 and heart rate.
- Comprehensive wellness metrics: Tracks sleep, activity, and temperature variability.
- Patient-friendly design: Flexible, comfortable ring improves compliance.
“We always envisioned the Evie Ring as a clinical-grade solution,” said John Mastrototaro, CEO of Movano Health. “This clearance allows us to deliver accurate, consistent, and comfortable health monitoring to healthcare providers, payors, and researchers.”
Collaborations and Future Plans
Movano Health is partnering with leading organizations, including a major payor and a global pharmaceutical company, to integrate the EvieMED Ring into clinical trials and chronic disease management. The device has also been selected for an MIT study on long COVID and chronic Lyme disease.
Future advancements include additional FDA clearances for respiration rate and RF-based analytes, such as cuffless blood pressure and noninvasive glucose monitoring.
Redefining Wearable Health Technology
The EvieMED Ring bridges the gap between consumer wearables and clinical-grade devices, providing reliable data for better health outcomes. Available in eight sizes, it accommodates diverse patient needs and offers inclusive accuracy across all skin tones.
Follow MEDWIRE.AI for the latest on FDA approved health monitoring innovations.
